Prof Milton Packer (Baylor University Medical Center, Dallas, TX, US), chief investigator of the EMPEROR-Reduced trial joined Dr Harriette Van Spall (McMaster University, Hamilton, CA) to discuss the results of the study. 

The purpose of EMPEROR-Reduced was to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.

Recorded remotely from Hamilton and Dallas, 2020. 

Recording Editor: Michael Knight

Editor: Mirjam Boros